- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Advanced Proteome Therapeutics Enters Collaboration to Develop Cancer Therapeutic
Advanced Proteome Therapeutics announced a collaboration with the National Research Council of Canada for the development of antibody-drug conjugates.
Advanced Proteome Therapeutics (TSXV:APC) announced a collaboration with the National Research Council of Canada for the development of antibody-drug conjugates.
As quoted in the press release:
Through recently signed collaborations, APC’s efforts are centered on antibody candidates that will be linked to drugs or toxins for the purpose of treating advanced solid tumors such as ovarian cancer, breast cancer, and non-small cell lung cancer, areas of ongoing therapeutic need in a more effective way.
“APC and the NRC will join forces to accurately evaluate the extent to which a drug (or toxin) has been attached to an antibody, validating our proprietary linker technology,” stated Allen Krantz, APC’s Founder and Chief Science Officer. “Scaling up and testing of the drug-linked candidates we produce, in cell models, will determine their potential as therapies and move APC one step closer to a commercialization.”
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.